Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:190165410 | Cervix | CC | response to ketone | 45/2311 | 194/18723 | 1.83e-05 | 3.44e-04 | 45 |
GO:00076238 | Cervix | CC | circadian rhythm | 46/2311 | 210/18723 | 6.76e-05 | 9.60e-04 | 46 |
GO:00325704 | Cervix | CC | response to progesterone | 13/2311 | 37/18723 | 2.99e-04 | 3.21e-03 | 13 |
GO:00329226 | Cervix | CC | circadian regulation of gene expression | 18/2311 | 68/18723 | 1.18e-03 | 9.56e-03 | 18 |
GO:0007623 | Colorectum | AD | circadian rhythm | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
GO:0048511 | Colorectum | AD | rhythmic process | 94/3918 | 298/18723 | 1.00e-05 | 2.34e-04 | 94 |
GO:0048545 | Colorectum | AD | response to steroid hormone | 104/3918 | 339/18723 | 1.33e-05 | 2.90e-04 | 104 |
GO:0019318 | Colorectum | AD | hexose metabolic process | 77/3918 | 237/18723 | 1.96e-05 | 4.01e-04 | 77 |
GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
GO:0005996 | Colorectum | AD | monosaccharide metabolic process | 80/3918 | 257/18723 | 7.31e-05 | 1.17e-03 | 80 |
GO:0006006 | Colorectum | AD | glucose metabolic process | 62/3918 | 196/18723 | 2.76e-04 | 3.39e-03 | 62 |
GO:0006109 | Colorectum | AD | regulation of carbohydrate metabolic process | 55/3918 | 178/18723 | 1.10e-03 | 1.01e-02 | 55 |
GO:1901654 | Colorectum | AD | response to ketone | 59/3918 | 194/18723 | 1.14e-03 | 1.04e-02 | 59 |
GO:0062012 | Colorectum | AD | regulation of small molecule metabolic process | 93/3918 | 334/18723 | 1.46e-03 | 1.24e-02 | 93 |
GO:00485451 | Colorectum | SER | response to steroid hormone | 80/2897 | 339/18723 | 5.15e-05 | 1.25e-03 | 80 |
GO:00076231 | Colorectum | SER | circadian rhythm | 54/2897 | 210/18723 | 7.98e-05 | 1.77e-03 | 54 |
GO:00193181 | Colorectum | SER | hexose metabolic process | 56/2897 | 237/18723 | 6.19e-04 | 8.42e-03 | 56 |
GO:00059961 | Colorectum | SER | monosaccharide metabolic process | 59/2897 | 257/18723 | 9.65e-04 | 1.15e-02 | 59 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491525 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa0491920 | Endometrium | AEH | Thyroid hormone signaling pathway | 30/1197 | 121/8465 | 1.20e-03 | 7.52e-03 | 5.50e-03 | 30 |
hsa04915111 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa04919110 | Endometrium | AEH | Thyroid hormone signaling pathway | 30/1197 | 121/8465 | 1.20e-03 | 7.52e-03 | 5.50e-03 | 30 |
hsa0491526 | Endometrium | EEC | Estrogen signaling pathway | 34/1237 | 138/8465 | 1.19e-03 | 8.02e-03 | 5.98e-03 | 34 |
hsa0491923 | Endometrium | EEC | Thyroid hormone signaling pathway | 29/1237 | 121/8465 | 4.08e-03 | 2.24e-02 | 1.67e-02 | 29 |
hsa0491535 | Endometrium | EEC | Estrogen signaling pathway | 34/1237 | 138/8465 | 1.19e-03 | 8.02e-03 | 5.98e-03 | 34 |
hsa0491933 | Endometrium | EEC | Thyroid hormone signaling pathway | 29/1237 | 121/8465 | 4.08e-03 | 2.24e-02 | 1.67e-02 | 29 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0491912 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa0491913 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa0491914 | Lung | IAC | Thyroid hormone signaling pathway | 27/1053 | 121/8465 | 1.61e-03 | 9.49e-03 | 6.30e-03 | 27 |
hsa0491516 | Lung | IAC | Estrogen signaling pathway | 28/1053 | 138/8465 | 5.64e-03 | 2.45e-02 | 1.63e-02 | 28 |
hsa0491915 | Lung | IAC | Thyroid hormone signaling pathway | 27/1053 | 121/8465 | 1.61e-03 | 9.49e-03 | 6.30e-03 | 27 |
hsa0491517 | Lung | IAC | Estrogen signaling pathway | 28/1053 | 138/8465 | 5.64e-03 | 2.45e-02 | 1.63e-02 | 28 |
hsa0491921 | Lung | AIS | Thyroid hormone signaling pathway | 27/961 | 121/8465 | 3.92e-04 | 3.85e-03 | 2.47e-03 | 27 |
hsa0491522 | Lung | AIS | Estrogen signaling pathway | 25/961 | 138/8465 | 1.18e-02 | 4.83e-02 | 3.09e-02 | 25 |
hsa0491931 | Lung | AIS | Thyroid hormone signaling pathway | 27/961 | 121/8465 | 3.92e-04 | 3.85e-03 | 2.47e-03 | 27 |
hsa0491532 | Lung | AIS | Estrogen signaling pathway | 25/961 | 138/8465 | 1.18e-02 | 4.83e-02 | 3.09e-02 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCOA2 | SNV | Missense_Mutation | | c.2933N>A | p.Gly978Glu | p.G978E | Q15596 | protein_coding | tolerated(0.11) | possibly_damaging(0.621) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCOA2 | SNV | Missense_Mutation | | c.826N>T | p.Leu276Phe | p.L276F | Q15596 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NCOA2 | SNV | Missense_Mutation | | c.703N>A | p.Pro235Thr | p.P235T | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
NCOA2 | SNV | Missense_Mutation | | c.254A>T | p.Glu85Val | p.E85V | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
NCOA2 | SNV | Missense_Mutation | novel | c.109N>T | p.Arg37Cys | p.R37C | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
NCOA2 | insertion | Frame_Shift_Ins | novel | c.2845_2846insGGTTTAGAAC | p.Met949ArgfsTer68 | p.M949Rfs*68 | Q15596 | protein_coding | | | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NCOA2 | SNV | Missense_Mutation | rs373466036 | c.3137N>T | p.Ala1046Val | p.A1046V | Q15596 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | rs777306143 | c.2485N>A | p.Ala829Thr | p.A829T | Q15596 | protein_coding | tolerated(0.25) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | novel | c.1830N>T | p.Lys610Asn | p.K610N | Q15596 | protein_coding | deleterious(0.02) | benign(0.138) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | rs375519556 | c.3389C>T | p.Ala1130Val | p.A1130V | Q15596 | protein_coding | deleterious(0.02) | benign(0.011) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |